2-butyl-4,6-dichloro-1,3,5-triazine | 4803-15-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 2-butyl-4,6-dichloro-1,3,5-triazine
• CAS: 4803-15-0
• 化学式: C₇H₉Cl₂N₃
• 分子量: 206.075
• InChiKey: FEHVKHFORSHUKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-butyl-4,6-dichloro-1,3,5-triazine 在 sodium hydrogen selenide 作用下， 以 水 、 丙酮 为溶剂， 以75%的产率得到4,6,10,12,16,18,19,20,21-nonaaza-5,11,17-tributyl-2,8,14-triselenacalix[3]arene
  参考文献：
  名称：

  Selenacalix[3]triazines: synthesis and host–guest chemistry

  摘要：

  通过与硒桥接的三元环状大环，杂二十六烯系列（N/O/S）得到了扩展。硒并六[3]三嗪是通过简便的一锅亲核芳香取代反应合成的，它们显示出奇特的超分子特征。N 型三叉结合袋既能配位铜离子，也能配位阴离子。

  DOI：

  10.1039/c1cc15473g
• 作为产物：
  描述：

  溴丁基-镁 、 三聚氯氰 以 四氢呋喃 为溶剂， 以80%的产率得到2-butyl-4,6-dichloro-1,3,5-triazine
  参考文献：
  名称：

  Selenacalix[3]triazines: synthesis and host–guest chemistry

  摘要：

  通过与硒桥接的三元环状大环，杂二十六烯系列（N/O/S）得到了扩展。硒并六[3]三嗪是通过简便的一锅亲核芳香取代反应合成的，它们显示出奇特的超分子特征。N 型三叉结合袋既能配位铜离子，也能配位阴离子。

  DOI：

  10.1039/c1cc15473g

文献信息

• 一种星型热激活延迟荧光材料、电子器件及其应用
  申请人：深圳大学

  公开号：CN111233914B

  公开（公告）日：2022-12-06

  本发明提供一种星型热激活延迟荧光材料、电子器件及其应用，属于有机电致发光技术领域。所述热激活延迟荧光材料，具有以下结构:本发明的星型三苯基苯衍生化合物具有热活化延迟荧光的性质，其以含氮杂环为电子给体(Donor)，与缺电子的受体(Acceptor)基团相连接，构成一类具有分子内电荷转移的D‑A型分子，同时利用D‑A之间大的扭转角以减小分子前线轨道的重叠，从而减小单重态‑三重态能级，使得三重态激子可通过反向系间穿越回到单重态，最后以辐射跃迁的方式回到基态发出荧光，以提高激子利用率，最终达到提高器件效率的目的。
• Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds
  申请人：Meguro Masaki

  公开号：US20050054732A1

  公开（公告）日：2005-03-10

  The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: (where, R 1 and R 2 are H or alkyl; Z 1 and Z 2 are H, alkyl, alkoxy, haloalkyl or halogeno; Z 3 is alkoxy, SH, alkylthio, NH 2 , mono- or di-alkylamino, OH or halogeno; Z 4 and Z 5 are H or halogeno; and A is 4,6-pyrimidine-1,3-diyl, 1,3,5-triazine-2,6-diyl, etc).

  本发明涉及预防或治疗阿尔茨海默病的药物或药物，或β淀粉样蛋白纤维形成抑制剂，其中包括通式（I）下的化合物或其药学上允许的盐作为活性成分；还涉及具有特定取代基的含氮杂环衍生物或其药学上允许的盐，其作为防治阿尔茨海默病的药物或β淀粉样蛋白纤维形成抑制剂具有价值：（其中，R1和R2是H或烷基；Z1和Z2是H，烷基，烷氧基，卤代烷基或卤素基；Z3是烷氧基，SH，烷硫基，NH2，单或双烷基氨基，OH或卤素基；Z4和Z5是H或卤素基；A是4,6-嘧啶-1,3-二基，1,3,5-三嗪-2,6-二基等）。
• Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound
  申请人：Meguro Masaki

  公开号：US20080182846A1

  公开（公告）日：2008-07-31

  The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: (where, R 1 and R 2 are H or alkyl; Z 1 and Z 2 are H, alkyl, alkoxy, haloalkyl or halogeno; Z 3 is alkoxy, SH, alkylthio, NH 2 , mono- or di-alkylamino, OH or halogeno; Z 4 and Z 5 are H or halogeno; and A is 4,6-pyrimidine-1,3-diyl, 1,3,5-triazine-2,6-diyl, etc).

  本发明涉及用于预防或治疗阿尔茨海默病的药物或疗法，或者用于抑制淀粉样蛋白纤维形成的药物，其中包括通式（I）所示的化合物或其药学上允许的盐作为活性成分；以及具有特定取代基的含氮杂环衍生物或其药学上允许的盐，它们对于预防或治疗阿尔茨海默病或作为淀粉样蛋白纤维形成抑制剂非常有价值。（其中，R1和R2为H或烷基；Z1和Z2为H、烷基、烷氧基、卤代烷基或卤素；Z3为烷氧基、SH、烷基硫醇、NH2、单烷基或二烷基氨基、OH或卤素；Z4和Z5为H或卤素；A为4,6-嘧啶-1,3-二基、1,3,5-三嗪-2,6-二基等）。
• Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound
  申请人：Meguro Masaki

  公开号：US20090286794A1

  公开（公告）日：2009-11-19

  The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: (where, R 1 and R 2 are H or alkyl; Z 1 and Z 2 are H, alkyl, alkoxy, haloalkyl or halogeno; Z 3 is alkoxy, SH, alkylthio, NH 2 , mono- or di-alkylamino, OH or halogeno; Z 4 and Z 5 are H or halogeno; and A is 4,6-pyrimidine-1,3-diyl, 1,3,5-triazine-2,6-diyl, etc).

  本发明涉及用于防治阿尔茨海默病的预防剂或治疗剂，或淀粉样蛋白纤维形成抑制剂，其包括以下通式（I）的化合物或其药理学许可盐作为活性成分；以及具有特定取代基的含氮杂芳基衍生物，或其药理学许可盐，它们作为防治阿尔茨海默病的预防剂或治疗剂，或淀粉样蛋白纤维形成抑制剂具有重要价值：（其中，R1和R2为H或烷基；Z1和Z2为H、烷基、烷氧基、卤代烷基或卤素；Z3为烷氧基、SH、烷硫基、NH2、单烷基或二烷基氨基、OH或卤素；Z4和Z5为H或卤素；A为4,6-嘧啶-1,3-二基、1,3,5-三嗪-2,6-二基等）。
• Anarchy in the solid state: structural dependence on glass-forming ability in triazine-based molecular glasses
  作者：James D. Wuest、Olivier Lebel

  DOI：10.1016/j.tet.2009.07.026

  日期：2009.9

  We have recently shown that molecular glasses, small molecules capable of readily forming glassy solids as opposed to crystals, can be designed by exploiting molecular association through strong and directional intermolecular interactions, as exemplified by several members of the bis(mexylantino)triazine family. Herein, 43 new bis(mexylamino)triazine derivatives were synthesized, 31 of which have been found to spontaneously form glassy phases and did not crystallize upon heating. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.